GRIN Therapeutics, Inc.
PrivateLast Round
Series D
May 28, 2025
Total Funding Raised
$140M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
GRIN Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series D round in May 2025.
GRIN Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops precision therapies for pediatric neurodevelopmental disorders. The company's primary focus is on its lead investigational drug, radiprodil, a negative allosteric modulator that selectively targets the GluN2B subunit of the NMDA receptor. This drug is being developed to treat GRIN-related neurodevelopmental disorder (GRIN-NDD), as well as other conditions like tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD). Founded in 2021, the company is an affiliate of Neurvati Neurosciences and a portfolio company of Blackstone Life Sciences. GRIN Therapeutics has received significant funding, including a $140 million Series D financing in May 2025, to advance radiprodil into a global Phase 3 clinical trial. The company has also entered a strategic collaboration with Angelini Pharma for the commercialization of radiprodil outside of North America.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GRIN Therapeutics, Inc. Comparables
Compare GRIN Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Noema Pharma | 76% | |
| Actio Biosciences | 73% | |
| Stoke Therapeutics, Inc. | 69% |
For institutional investors. Book with your work email.
GRIN Therapeutics, Inc. Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
GRIN Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blackstone Life Sciences | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 98% MoM, reaching 2.1K.
- Dec 11, 2025
Partnered with InformedDNA to offer free genetic counseling to US patients.
For institutional investors. Book with your work email.
GRIN Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GRIN Therapeutics, Inc.'s valuation, stock price, and market status.
Is GRIN Therapeutics, Inc. a public or private company?
GRIN Therapeutics, Inc. is a private company.
What is the current stock price of GRIN Therapeutics, Inc.?
GRIN Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks GRIN Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GRIN Therapeutics, Inc. worth (valuation)?
Valuation information for GRIN Therapeutics, Inc. is not publicly available.
Can I buy GRIN Therapeutics, Inc. stock?
GRIN Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GRIN Therapeutics, Inc.'s last funding round?
GRIN Therapeutics, Inc.'s most recent funding round was Series D on May 28, 2025.
Who are the main investors in GRIN Therapeutics, Inc.?
Key investors in GRIN Therapeutics, Inc. include Blackstone Life Sciences.
Will GRIN Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for GRIN Therapeutics, Inc..
How can I track GRIN Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in GRIN Therapeutics, Inc.'s shares on secondary markets.